Browse by Medical Category
Accepting New Patients
Go To Programs
Go To Specialties
MassGeneral Hospital for Children
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Jessica Sachs has been a member of the MGH Division of Pediatric Hematology and Oncology faculty since 2010. She divides her time between patient care, and clinical and translational research. Her research interests center around T cell immunology and cell therapy, specifically developing ways to harness the immune system to treat cancer. Her clinical work focuses on care for children and adolescents with blood disorders and cancer.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J ; ECHELON-1 Study Group. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. NEJM. 2018 Jan 25 ;378(4) :331-344.
Sachs J and Li H, Pichardo C, Bronson R, Zhao G, Sykes M. Nonalloreactive T cells Prevent Donor Lymphocyte Infusion-Induced Graft-versus-Host Disease by Controlling Microbial Stimuli. J Immunol. 2012 ; 189 :5572-5581.
Pai SY, Levy O, Jabara HH, Glickman JN, Stoler-Barak L, Sachs J, Nurko S, Orange JS, Geha RS. Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-kappaB essential modulator deficiency. J Allergy Clin Immunol. 2008 Dec;122(6):1113-1118.e1. Epub 2008 Oct 11.
Saad AG, Sachs J, Turner CD, Procton M, Marcus KJ, Wang L, Lidov H, Ullrich NJ. Extracranial Metastases of Glioblastoma in a Child: Case Report and Review of the Literature. Journal of Pediatric Oncology. 2007 Mar; 29(3):190-194.
Chakraverty R, Eom HS, Sachs J, Buchli J, Cotter P, Hsu R, Zhao G, Sykes M. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood. 2006 Sep 15; 108(6): 2106-13.
Back to Top